Can Nanosonics Ltd join the likes of Cochlear Limited and Resmed Inc?

The start of something exciting?

| More on:
a woman

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Biotech Nanosonics Ltd (ASX: NAN) has the big aim of joining the likes of Cochlear Limited (ASX: COH) and Resmed Inc (ASX: RMD) as great Australian medical technology stocks.

In an update to the market today, Nanosonics reported full financial year sales of $21.5 million, up 44% over the prior year. That continues a great trend over the past three years, with revenues rising 21% in 2013 and 447% in 2012.

The company says it has $21.2 million in cash at the end of June, and received another $3 million in July relating to sales in the fourth quarter. Nanosonics chief executive officer Michael Kavanagh was upbeat about the result, "The strong results and growth momentum coupled with strengthening market fundamentals provide confidence in our goal of establishing trophon as a new standard of care."

Nanosonics sells Trophon, which is designed to achieve high-level disinfection of ultrasound probes more effectively than existing common methods such as topical sprays and disinfecting wipes. According to the company, Trophon systems are fast – taking just 7 minutes to disinfect probes, produces environmentally friendly by-products of water and oxygen, and is safe for users. When healthcare acquired infections kill more people in the US than breast cancer and prostate cancer combined – and 70% could be prevented with existing prevention measures – you know its a serious issue.

At a current market of just over $200 million, this could be the start of something very exciting. In May this year, GE Healthcare showcased Trophon at a conference of medical professionals. And the American Institute of Ultrasound in Medicine (AIUM) updated its guidelines and reinforced stricter controls for high-level disinfection during the quarter.

With growing awareness around the globe of the need for better disinfection solutions, Nanosonics appears to have several tailwinds behind it, which could propel sales and earnings much further.

Nanosonics is one company you might want to watch.

Motley Fool writer/analyst Mike King owns shares in Cochlear and Resmed. You can follow Mike on Twitter @TMFKinga

More on ⏸️ Investing

Close up of baby looking puzzled
Retail Shares

What has happened to the Baby Bunting (ASX:BBN) share price this year?

It's been a volatile year so far for the Aussie nursery retailer. We take a closer look

Read more »

woman holds sign saying 'we need change' at climate change protest
ETFs

3 ASX ETFs that invest in companies fighting climate change

If you want to shift some of your investments into more ethical companies, exchange-traded funds can offer a good option

Read more »

a jewellery store attendant stands at a cabinet displaying opulent necklaces and earrings featuring diamonds and precious stones.
⏸️ Investing

The Michael Hill (ASX: MHJ) share price poised for growth

Investors will be keeping an eye on the Michael Hill International Limited (ASX: MHJ) share price today. The keen interest…

Read more »

ASX shares buy unstoppable asx share price represented by man in superman cape pointing skyward
⏸️ Investing

The Atomos (ASX:AMS) share price is up 15% in a week

The Atomos (ASX: AMS) share price has surged 15% this week. Let's look at what's ahead as the company build…

Read more »

Two people in suits arm wrestle on a black and white chess board.
Retail Shares

How does the Temple & Webster (ASX:TPW) share price stack up against Nick Scali (ASX:NCK)?

How does the Temple & Webster (ASX: TPW) share price stack up against rival furniture retailer Nick Scali Limited (ASX:…

Read more »

A medical researcher works on a bichip, indicating share price movement in ASX tech companies
Healthcare Shares

The Aroa (ASX:ARX) share price has surged 60% since its IPO

The Aroa (ASX:ARX) share price has surged 60% since the Polynovo (ASX: PNV) competitor listed on the ASX in July.…

Read more »

asx investor daydreaming about US shares
⏸️ How to Invest

How to buy US shares from Australia right now

If you have been wondering how to buy US shares from Australia to gain exposure from the highly topical market,…

Read more »

⏸️ Investing

Why Fox (NASDAQ:FOX) might hurt News Corp (ASX:NWS) shareholders

News Corporation (ASX: NWS) might be facing some existential threats from its American cousins over the riots on 6 January

Read more »